Vericel Corporation has secured a significant ten-year contract worth up to $197 million from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to enhance national preparedness for severe burn and blast trauma injuries. This contract, which became effective on April 1, 2026, includes a base period of $35 million for the initial procurement of NexoBrid, a biological agent for eschar removal in burn patients, and outlines plans for the development of a next-generation formulation and expanded indications.

This partnership underscores the growing recognition of the clinical value of NexoBrid in emergency medicine and trauma care, particularly in scenarios involving mass casualty events. The funding will support the establishment of a Vendor Managed Inventory (VMI) system and the design of a U.S.-based manufacturing facility, which could significantly enhance the availability of this critical therapeutic agent. Additionally, the potential expansion of NexoBrid’s indications to include blast trauma injuries reflects a broader trend in the field toward integrating advanced therapies into emergency response protocols.

For professionals in aging biology and healthspan research, this development highlights the intersection of advanced therapeutics and emergency preparedness. The implications of such contracts extend beyond immediate clinical applications, suggesting a growing market for innovative therapies that address acute medical needs in aging populations, who are often at higher risk for severe injuries. As the field evolves, the integration of advanced biological therapies like NexoBrid into standard care practices may pave the way for improved outcomes in trauma care, ultimately contributing to enhanced healthspan.

Source: globenewswire.com